Evidence map›Paper›PMID 20029710›Full record

Trial reportJournal of health communication2009

Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.

Sato Ashida, Laura M Koehly, J Scott Roberts, Clara A Chen, Susan Hiraki, Robert C Green

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of health communication, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. What Psychiatrists Should Know about Genes and Alzheimer's Disease.Psychiatry (Edgmont (Pa. : Township)) · 2010
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Sato AshidaSocial and Behavioral Research Branch, National Human Genome Research Institute, Bethesda, Maryland 20892-2073, USA. ashidas@mail.nih.gov
Laura M Koehly
J Scott Roberts
Clara A Chen
Susan Hiraki
Robert C Green
Boston University · USNational Human Genome Research Institute · USBoston Public Schools · USMichigan Department of Health and Human Services · US

Funding

Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1M
YOGA INDUCED CHANGES IN BRAIN GABA LEVELSM01RR000533 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HOLICK, MICHAEL F. · 1985 to 2008
$19.4M
GENETIC EPIDEMIOLOGICAL STUDIES OF ALZHEIMERS DISEASER01AG009029 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FARRER, LINDSAY A. · 1991 to 2007
$14.7M
The influence of familial social context on risk dissemination and copingZIAHG200335 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI KOEHLY, LAURA M · 2009 to 2025
$13.6M
The influence of familial social context on risk dissemination and copingZ01HG200335 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI KOEHLY, LAURA M · 2006 to 2008
$1.2M
Characterizing Communicating Genetic Risk Alzheimer'sK24AG027841 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 2006 to 2010
$914k
Intramural NIH HHS Z01 HG200335NCRR NIH HHS M01 RR000533NCRR NIH HHS M01 RR00533NIA NIH HHS K24 AG027841NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG13846NIA NIH HHS R01 AG009029NIA NIH HHS R01 AG09029NIA NIH HHS R01 HG/AG02213
6 · The paper itself

Abstract

This study explored the extent to which recipients of genetic susceptibility testing for Alzheimer's disease (AD) communicated their results to others. It also examined demographic characteristics, along with beliefs about AD, associated with such communication. Participants (N = 271) in a randomized clinical trial involving genetic testing for Apolipoprotein E (APOE) gene variants among first-degree relatives of AD patients reported their communication behaviors 6 weeks after the results disclosure. Information on beliefs about AD and genetic testing was collected at baseline. Eighty-two percent of participants receiving APOE genotype information shared their results with someone. Specifically, 64% shared with family members, 51% with spouse or significant others, 35% with friends, and 12% with health care professionals. Greater AD treatment optimism was associated with communicating results to family (OR = 1.43), spouse (OR = 1.62), friends (OR = 1.81), and health care professionals (OR = 2.20). Lower perceived risk (OR = 0.98) and higher perceived importance of genetics in the development of AD (OR = 1.93) were associated with results communication in general. Lower perceived drawbacks of AD genetic testing was associated with results communication to friends (OR = 0.65). Beliefs about AD risks and causes, genetic testing, and development of treatments partly may determine the interpersonal communication patterns of genetic susceptibility test results.

Indexed as

Self DisclosureAdultAgedAged, 80 and overAlzheimer DiseaseApolipoproteins EFemaleGenetic Predisposition to DiseaseGenetic TestingHumansMaleMiddle AgedApolipoproteins E

Identifiers

PMID20029710
PMCPMC2801901
OpenAlexW2169669897

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.